Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening, MCED Test Development and MRD Test Development. The Companyâs products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, and OncoExTra Test. The Companyâs flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patientâs breast tumor tissue.

Employees

6,550

Sector

Biotechnology & Medical Research

Calendar

2024-12-11 - San Antonio Breast Cancer Symposium - Poster P1-01-23

More about the company

Quotes

Date	Price	Change	Volume
24-12-06	62.46 $	-0.24%	2,263,398
24-12-05	62.61 $	-2.39%	1,903,306
24-12-04	64.14 $	+5.91%	2,630,648
24-12-03	60.56 $	-1.83%	2,556,584
24-12-02	61.69 $	-0.63%	1,801,774

Delayed Quote Nasdaq, December 06, 2024 at 04:00 pm EST

More quotes

Income Statement and Estimates

income-statement-evolution-chart EXACT-SCIENCES-CORPORATIO

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

62.46USD

Average target price

70.81USD

Spread / Average Target

+13.37%

Consensus

Profit revisions

estimates-change-chart EXACT-SCIENCES-CORPORATIO

Estimate revisions

Quarterly revenue - Rate of surprise

quality-estimates-chart EXACT-SCIENCES-CORPORATIO

Company calendar

Market Closed - Nasdaq Other stock markets 04:00:00 2024-12-06 pm EST			5-day change	1st Jan Change
62.46 ^USD	-0.24%		+0.61%	-15.57%

Dec. 04	Exact Sciences Corporation Presents at 7th Annual Evercore ISI HealthCONx Healthcare Conference, Dec-04-2024 07:30 AM
Dec. 03	Exact Sciences Corporation Presents at Citi's 2024 Global Healthcare Conference, Dec-03-2024 08:45 AM

Capitalization	11.56B 10.94B 10.14B 9.07B 16.34B 979B 18.09B 126B 46.65B 402B 43.42B 42.46B 1,733B	P/E ratio 2024 *	-53.6x	P/E ratio 2025 *	-156x
Enterprise value	13.33B 12.62B 11.69B 10.46B 18.85B 1,129B 20.86B 146B 53.79B 464B 50.08B 48.96B 1,999B	EV / Sales 2024 *	4.86x	EV / Sales 2025 *	4.3x
Free-Float	98.92%	Yield 2024 *	-	Yield 2025 *	-

Exact Sciences Corporation Presents at 7th Annual Evercore ISI HealthCONx Healthcare Conference, Dec-04-2024 07:30 AM	Dec. 04
Exact Sciences Corporation Presents at Citi's 2024 Global Healthcare Conference, Dec-03-2024 08:45 AM	Dec. 03
Exact Sciences Corp. and Lil Jon Partner on "Get Low #2" Campaign to Encourage Colon Cancer Screening	Dec. 02	CI
BTIG Raises Price Target on Exact Sciences to $75 From $65, Maintains Buy Rating	Nov. 26	MT
Exact Sciences Corporation Presents at Jefferies London Healthcare Conference 2024, Nov-19-2024 11:00 AM	Nov. 19
Exact Sciences Insider Bought Shares Worth $1,001,325, According to a Recent SEC Filing	Nov. 13	MT
Wall Street Cheers Trump Election Win as US Equity Futures Rise Pre-Bell	Nov. 06	MT
Global markets live: Nvidia, Apple, Chevron, KKR, CVS Health...	Nov. 06
Markets mobilize as Donald dominates	Nov. 06
Top Premarket Decliners	Nov. 06	MT
Analyst recommendations: Snap, Qualys, Sirius XM, Super Micro Computer, Burberry...	Nov. 06
Exact Sciences Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	Nov. 05	CI
Exact Sciences Corporation, Q3 2024 Earnings Call, Nov 05, 2024	Nov. 05

BTIG Raises Price Target on Exact Sciences to $75 From $65, Maintains Buy Rating	Nov. 26	MT
Analyst recommendations: Snap, Qualys, Sirius XM, Super Micro Computer, Burberry...	Nov. 06
Analyst recommendations: 3M Company, GM, IBM, Robinhood, Moonpig...	Oct. 29
Wells Fargo Global Initiates Exact Sciences at Overweight With $75 Price Target	Aug. 28	MT
UBS Cuts Exact Sciences' Price Target to $61 From $66, Maintains Neutral Rating	Aug. 01	MT

Exact Sciences Corporation Stock

Equities

EXAS

US30063P1057

Biotechnology & Medical Research

Valuation: Exact Sciences Corporation

Chart: Exact Sciences Corporation

Latest news: Exact Sciences Corporation

Last Transcript: Exact Sciences Corporation

Analysts' recommendations: Exact Sciences Corporation

Press Releases: Exact Sciences Corporation

News in other languages: Exact Sciences Corporation

Quotes and Performance

Course Extremes

Managers and Directors: Exact Sciences Corporation

ETFs: Exact Sciences Corporation

Bio Diagnostics & Testing

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly revenue - Rate of surprise

Tel Aviv University: Exposing Hamas' Ground Movements on October 7th with Seismic Data	Nov. 29	AQ
Exact Sciences Advances Breast Cancer Care with the Oncotype DX test and Genomic Profiling Research at SABCS 2024	Nov. 26	AQ
Exact Sciences to Participate in December Investor Conferences	Nov. 26	BU
Exact Sciences Advances Breast Cancer Care with the Oncotype DX® test and Genomic Profiling Research at SABCS 2024	Nov. 25	BU
Exact Sciences Unveils Data Showing Promise of Multi-Cancer Early Detection at AACR Special Conference on Liquid Biopsy	Nov. 13	BU

MÄRKTE USA/Wall Street von Trump auf Rekordhochs getrieben	Nov. 06
MÄRKTE USA/Trump treibt Wall Street auf Rekordhochs	Nov. 06
En Direct des marchés : Jour J pour Novo Nordisk, Super Micro Computer chute et NVIDIA numéro 1	Nov. 06
En attente du point de bascule	Nov. 06
ASCO®: Exact Sciences bekräftigt mit mehreren Datenpräsentationen seine langfristige Vorreiterrolle in der Krebsfrüherkennung und bei der Verbesserung von Behandlungsergebnissen	May. 25

1 day	-0.24%
1 week	+0.61%
Current month	+0.61%
1 month	+14.14%
3 months	+5.67%
6 months	+39.83%
Current year	-15.57%

Director	Title	Age	Since
Kevin Conroy CEO	Chief Executive Officer	58	2009-03-17
Aaron Bloomer DFI	Director of Finance/CFO	38	2024-04-14
Tomasz Beer CTO	Chief Tech/Sci/R&D Officer	-	2021-12-31

Manager	Title	Age	Since
Kevin Conroy CHM	Chairman	58	2014-03-20
Katherine Zanotti BRD	Director/Board Member	69	2009-04-28
Daniel Levangie BRD	Director/Board Member	74	2010-07-18

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
EXACT SCIENCES CORPORATION	-0.24%	+0.61%	-4.14%	-22.74%	11.56B
VERACYTE, INC.	+3.01%	+2.75%	+71.78%	+17.37%	3.42B
IOVANCE BIOTHERAPEUTICS, INC.	+6.61%	-3.11%	+41.54%	-46.66%	2.75B
BGI GENOMICS CO., LTD.	+4.55%	+4.27%	-6.36%	-47.20%	2.5B
CAREDX, INC	+1.38%	+2.04%	+159.75%	-41.77%	1.34B
ADAPTIVE BIOTECHNOLOGIES CORPORATION	+3.29%	+5.56%	+35.71%	-75.09%	925M
SEEGENE, INC.	+1.10%	-3.58%	-9.13%	-64.50%	744M
MARAVAI LIFESCIENCES HOLDINGS, INC.	-0.79%	-10.93%	-5.43%	-87.60%	716M
VIMTA LABS LIMITED	+2.24%	+3.73%	+124.36%	+122.25%	246M
CURIOX BIOSYSTEMS CO., LTD	-5.68%	-1.74%	-24.89%	-	210M
Average	+1.55%	+0.05%	+38.32%	-27.33%	2.44B
Weighted average by Cap.	+1.70%	+0.61%	+22.87%	-27.10%

	2024 *	2025 *
Net sales	2.74B 2.59B 2.4B 2.15B 3.87B 232B 4.29B 29.91B 11.06B 95.35B 10.29B 10.07B 411B	3.05B 2.89B 2.68B 2.4B 4.32B 259B 4.78B 33.34B 12.32B 106B 11.47B 11.22B 458B
Net income	-222M -210M -195M -174M -314M -18.82B -348M -2.43B -897M -7.73B -835M -816M -33.32B	-87.9M -83.18M -77.11M -68.96M -124M -7.44B -138M -959M -355M -3.06B -330M -323M -13.18B
Net Debt	1.77B 1.68B 1.55B 1.39B 2.5B 150B 2.77B 19.33B 7.15B 61.63B 6.65B 6.51B 266B	1.58B 1.5B 1.39B 1.24B 2.24B 134B 2.48B 17.27B 6.38B 55.05B 5.94B 5.81B 237B